Long-term follow-up of rituximab plus bendamustine and cytarabine in older patients with newly diagnosed MCL

The combination of rituximab, bendamustine, and low-dose cytarabine (R-BAC) has been studied in a phase 2 prospective multicenter study from Fondazione Italiana Linfomi (RBAC500). In 57 previously untreated elderly patients with mantle cell lymphoma (MCL), R-BAC was associated with a complete remiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Tisi, Maria Chiara, Moia, Riccardo, Patti, Caterina, Evangelista, Andrea, Ferrero, Simone, Spina, Michele, Tani, Monica, Botto, Barbara, Celli, Melania, Puccini, Benedetta, Cencini, Emanuele, Di Rocco, Alice, Chini, Claudio, Ghiggi, Chiara, Zambello, Renato, Zanni, Manuela, Sciarra, Roberta, Bruna, Riccardo, Ferrante, Martina, Pileri, Stefano Alessandro, Quaglia, Francesca Maria, Stelitano, Caterina, Re, Alessandro, Volpetti, Stefano, Zilioli, Vittorio Ruggero, Arcari, Annalisa, Merli, Francesco, Visco, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405197/
https://www.ncbi.nlm.nih.gov/pubmed/37171620
http://dx.doi.org/10.1182/bloodadvances.2023009744

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10405197/
https://www.ncbi.nlm.nih.gov/pubmed/37171620
http://dx.doi.org/10.1182/bloodadvances.2023009744

Ejemplares similares